Study: Anti-NGF drug could be effective treatment for OA patients

04/16/2013 | InternalMedicineNews.com (free registration)

Treatment of osteoarthritis of the hip with tanezumab, an anti-nerve growth factor, was found to significantly improve pain and physical function after 16 weeks, according to results from a Phase III study of 621 patients with painful hip OA. According to the study, tanezumab could be useful in treating OA patients who can't tolerate or don't respond to nonopioid treatments.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC